Paediatrics

Children are not minature versiosns of adults. The paediatric population ranges from pre-term newborns, through toddlers and children to adolescents. The functions and maturity of their major organs can result in different effects of medicines on their bodies from those observed in adults.

The importance of “making medicines child-sized”, in establishing appropriate doses and preparations of medicines for children is a key priority in the safe and effective treatment of sick children.

The European Commission has established legislation to promote the development of Paediatric medicines, with incentives which offer protection of data and a period of exclusivity.

Auralis’s portfolio of Paediatric products in development focus on studies dedicated to providing evidence for specific paediatric use of off-patent medicines and products currently used off-label.